Close Menu

Lung Cancer

News and reporting on lung cancer.

Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.

Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.

The assay will include a multiplexed panel of established and emerging biomarkers and will be the first RNA-based assay on the Idylla platform using FFPE samples. 

The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.

The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.

The funding is being provided under the NYGC's Polyethnic-1000 initiative, which was launched in 2018 to study cancer care inequities in underserved populations.

In PNAS this week: possible treatment targets in KRAS-mutated lung cancer, transcriptional analysis of mouse models lacking a p53 inhibitor, and more.

The goal of the project is to build a liquid biopsy-based early detection technology platform and develop tests for lung and digestive system cancers.

The agency approved the test for use across solid tumors and with multiple companion diagnostic indications including one for prostate cancer and three for lung cancer.

The San Diego-based firm anticipates launching an LDT for early-stage lung cancer out of a CLIA-certified, CAP-accredited lab within the next two years.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.